Companies / Impact Biomedical Inc.

Impact Biomedical Inc.

NYSE: IBOCIK 1834105HOUSTON, TX

Financials · FY2025

Revenue$32.0K
Net income$-11.87M
Total debt$11.90M
Cash$20.0K
Diluted EPS$-0.38
Shares outstanding107.8M

Ownership

107.8M shares outstanding · as of Aug 4, 2026
0.38%Insiders
Ownership
Insiders0.38%405,304
10%+ / strategic0.51%545,024
Institutions2.92%3,153,227
Public float96.19%103,717,676

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 3

View all →
Insider% of sharesShares
Dss, Inc.10% owner
0.51%545,024
Grady JasonDirector
0.23%250,182
Macko Todd DChief Financial Officer
0.14%155,122

Institutional holders 25

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon Stock$671.6K+1.1M
+1503.87%
1,192,925
1.11% of shares
low
Q2 2026
as of
State Street Corporation
13F manager
AddCommon Stock$274.2K+596K
+5052.98%
607,897
0.56% of shares
low
Q1 2026
as of
Millennium Management LLC
13F manager
ExitCommon Stock$-69.6K-138K
-100.00%
low
Q4 2024
as of
Barclays PLC
13F manager
ExitCommon Stock$-2.2K-1K
-100.00%
low
Q3 2024
as of
Barclays PLC
13F manager
NewCommon Stock$2.2K+1K
1,120
<0.01% of shares
low
Q1 2026
as of
Two Sigma Investments, LP
13F manager
TrimCommon Stock$-1.4K-2K
-6.03%
37,427
0.03% of shares
low
Q4 2025
as of
Bank of America Corp /De
13F manager
AddCommon Stock$382+756
+450.00%
924
<0.01% of shares
low
Q3 2024
as of
Danske Bank A/S
13F manager
NewCommon Stock$6+3
3
<0.01% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
IBOCommon StockEquity45259L205BBG01JFZG014